RemedyRepack, a drug repackager in Indiana, Pennsylvania, failed CGMP, including cleaning and beta-lactam cross-contamination controls.
What happened
FDA inspected RemedyRepack’s drug manufacturing facility in Indiana, Pennsylvania, from November 7 to November 10, 2022. The agency found inadequate cleaning of equipment, including contaminated surfaces and visibly contaminated tablets and capsules, and it said the company lacked chemical testing to confirm cleaning. FDA also found inadequate investigations of broken tablets, packaging processes without adequate validation, and non-penicillin beta-lactam drugs repackaged in the same facility as non-beta-lactam drugs without complete separation.
What FDA found
The company’s written procedures for cleaning and maintaining drug manufacturing equipment were inadequate, and quality checks did not catch contaminated surfaces.
21 CFR 211.67(b)The company did not thoroughly investigate unexplained discrepancies or batch failures, such as repeated broken tablets during packaging, and did not determine root causes or corrective actions.
21 CFR 211.192The company lacked adequate written production and process control procedures and did not validate its drug packaging processes or qualify packaging equipment.
21 CFR 211.100(a)The company did not have separate or defined areas to prevent contamination or mix-ups and repackaged non-penicillin beta-lactam drugs in the same facility as non-beta-lactam drugs.
21 CFR 211.42(c)
What FDA wants
FDA asks RemedyRepack to correct the violations and respond in writing within 15 working days with corrective actions, including cleaning and investigation assessments, process validation, and beta-lactam separation or decontamination plans. FDA also strongly recommends engaging a qualified CGMP consultant.
Who should pay attention
- companies that buy repackaged drugs from RemedyRepack
- pharmacies and patients receiving repackaged tablets or capsules
- contract manufacturers or repackagers handling beta-lactam and non-beta-lactam drugs
This is a summary. Read the original letter on fda.gov.